Haim Michael Barr

The paper compares three data analysis methods for MERS-CoV MPro inhibitors, finding that modeling the complete concentration-response curve best predicts cellular efficacy.

This paper introduces PINCHs, bifunctional molecules that sequester homomeric proteins by inducing polymerization, demonstrating efficacy in knocking down protein function in cells.

The paper identifies fragment binders and mutationally intolerant sites in Zika virus NS2B-NS3 protease to develop resistance-resilient antiviral inhibitors.

This paper introduces a computational pipeline for identifying broad-spectrum antivirals by analyzing viral sequences, predicting ligand poses, and scoring protein-ligand complexes, validated on SARS-CoV-2 and MERS-CoV datasets.

This study identifies potential treatments for Kaposiform Lymphangiomatosis using a zebrafish model and high-throughput drug screening.

The paper identifies orally bioavailable inhibitors of the Zika virus NS2B-NS3 protease that show antiviral activity in vitro and reduce viral RNA load in a murine infection model.

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

The paper identifies potent nsp3-mac1 inhibitors but finds they do not translate to antiviral activity in cell culture models.

This paper uses unsupervised machine learning to identify active fragments from crystallographic data, distinguishing them from inactive ones without activity data.